After a 27-month rollercoaster ride, can we expect a return to normal?
Battered biotech is reviving after booming and busting in spectacular fashion. M&A is heating up as pharma companies face up to their patent cliff. And drug sales growth forecasts continue skyward.
Big pharma had a smoother ride– not just relative to biotech, but as a defensive stalwart amid huge macro-economic pressures. Then of course there’s the unpredictability of China and a hard-to-read FDA to consider.
The Evaluate Pharma World Preview 2022 explores the future of the pharma and biotech landscape, based on Evaluate consensus forecasts out to 2028.